Literature DB >> 15818469

Familial hypobetalipoproteinemia: genetics and metabolism.

G Schonfeld1, X Lin, P Yue.   

Abstract

Familial hypobetalipoproteinemia (FHBL), an autosomal dominant disorder, is defined as <5th percentile LDL-cholesterol or apolipoprotein (apo) B in the plasma. FHBL subjects are generally heterozygous and asymptomatic. Three genetic forms exist: (i) premature stop codon specifying mutations of APOB; (ii) FHBL linked to a susceptibility locus on the chromosome 3p21; and (iii) FHBL linked neither to APOB nor to the chromosome 3p21. In heterozygous apoB-defective FHBL, the hepatic VLDL export system is defective because apoB 100, the product of the normal allele, is produced at approximately 25% of normal rate, and truncated apoB is cleared too rapidly. The reduced capacity for hepatic triglyceride export increases hepatic fat three-fold. Indexes of adiposity and insulin action are similar to controls. 'Knock-in' mouse models of apoB truncations resemble human FHBL phenotypes. Liver fat in the chromosome 3p21-linked FHBL is normal. Elucidation of the genetic basis of the non-apoB FHBL could uncover attractive targets for lipid-lowering therapy. (See note added in proof.).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15818469     DOI: 10.1007/s00018-005-4473-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  20 in total

1.  Guidelines on myocardial revascularization.

Authors:  William Wijns; Philippe Kolh; Nicolas Danchin; Carlo Di Mario; Volkmar Falk; Thierry Folliguet; Scot Garg; Kurt Huber; Stefan James; Juhani Knuuti; Jose Lopez-Sendon; Jean Marco; Lorenzo Menicanti; Miodrag Ostojic; Massimo F Piepoli; Charles Pirlet; Jose L Pomar; Nicolaus Reifart; Flavio L Ribichini; Martin J Schalij; Paul Sergeant; Patrick W Serruys; Sigmund Silber; Miguel Sousa Uva; David Taggart
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

2.  Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock.

Authors:  René J van der Schaaf; Bimmer E Claessen; M Marije Vis; Loes P Hoebers; Karel T Koch; Jan Baan; Martijn Meuwissen; Annemarie E Engstrom; Wouter J Kikkert; Jan G P Tijssen; Robbert J de Winter; Jan J Piek; José P S Henriques
Journal:  Am J Cardiol       Date:  2010-02-13       Impact factor: 2.778

3.  Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis.

Authors:  Pieter J Vlaar; Karim D Mahmoud; David R Holmes; Gert van Valkenhoef; Hans L Hillege; Iwan C C van der Horst; Felix Zijlstra; Bart J G L de Smet
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

4.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

Authors:  Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

5.  Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial.

Authors:  Holger Thiele; Steffen Desch; Jan J Piek; Janina Stepinska; Keith Oldroyd; Pranas Serpytis; Gilles Montalescot; Marko Noc; Kurt Huber; Georg Fuernau; Suzanne de Waha; Roza Meyer-Saraei; Steffen Schneider; Stephan Windecker; Stefano Savonitto; Andrew Briggs; Patrizia Torremante; Christiaan Vrints; Gerhard Schuler; Uta Ceglarek; Joachim Thiery; Uwe Zeymer
Journal:  Am Heart J       Date:  2015-12-01       Impact factor: 4.749

6.  Use and outcomes of multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicated by cardiogenic shock (from the EHS-PCI Registry).

Authors:  Timm Bauer; Uwe Zeymer; Matthias Hochadel; Helge Möllmann; Franz Weidinger; Ralf Zahn; Holger M Nef; Christian W Hamm; Jean Marco; Anselm K Gitt
Journal:  Am J Cardiol       Date:  2012-01-09       Impact factor: 2.778

7.  Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial.

Authors:  John G Webb; April M Lowe; Timothy A Sanborn; Harvey D White; Lynn A Sleeper; Ronald G Carere; Christopher E Buller; S Chiu Wong; Jean Boland; Vlad Dzavik; Mark Porway; Gordon Pate; Geoffrey Bergman; Judith S Hochman
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

8.  Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.

Authors:  D W Muller; E J Topol; S G Ellis; K N Sigmon; K Lee; R M Califf
Journal:  Am Heart J       Date:  1991-04       Impact factor: 4.749

9.  Randomized trial of preventive angioplasty in myocardial infarction.

Authors:  David S Wald; Joan K Morris; Nicholas J Wald; Alexander J Chase; Richard J Edwards; Liam O Hughes; Colin Berry; Keith G Oldroyd
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

10.  Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Authors:  Anthony H Gershlick; Jamal Nasir Khan; Damian J Kelly; John P Greenwood; Thiagarajah Sasikaran; Nick Curzen; Daniel J Blackman; Miles Dalby; Kathryn L Fairbrother; Winston Banya; Duolao Wang; Marcus Flather; Simon L Hetherington; Andrew D Kelion; Suneel Talwar; Mark Gunning; Roger Hall; Howard Swanton; Gerry P McCann
Journal:  J Am Coll Cardiol       Date:  2015-03-17       Impact factor: 24.094

View more
  31 in total

1.  Clinical-pathological conference series from the Medical University of Graz : case no. 131: elevated transaminases in a 30-year-old male.

Authors:  Csilla Putz-Bankuti; Christian Datz; Winfried März; Carolin Lackner; Rudolf E Stauber; Michael Trauner; Hermann Toplak; Tatjana Stojakovic; Guenter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2006-12       Impact factor: 1.704

Review 2.  LDL-C-lowering therapy: current and future therapeutic targets.

Authors:  Maartje E Visser; Lily Jakulj; John J P Kastelein; Erik S G Stroes
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

3.  Does inhibition of apolipoprotein B synthesis produce foie gras?

Authors:  Kenneth R Feingold
Journal:  J Lipid Res       Date:  2009-12-30       Impact factor: 5.922

4.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

5.  Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.

Authors:  Ilenia Minicocci; Sara Santini; Vito Cantisani; Nathan Stitziel; Sekar Kathiresan; Juan Antonio Arroyo; Gertrudis Martí; Livia Pisciotta; Davide Noto; Angelo B Cefalù; Marianna Maranghi; Giancarlo Labbadia; Giovanni Pigna; Fabio Pannozzo; Fabrizio Ceci; Ester Ciociola; Stefano Bertolini; Sebastiano Calandra; Patrizia Tarugi; Maurizio Averna; Marcello Arca
Journal:  J Lipid Res       Date:  2013-09-20       Impact factor: 5.922

Review 6.  Update on primary hypobetalipoproteinemia.

Authors:  Amanda J Hooper; John R Burnett
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

7.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

8.  Fatty liver and insulin resistance: not always linked.

Authors:  Gustav Schonfeld; Pin Yue; Xiaobo Lin; Zhouji Chen
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

Review 9.  Diagnosis and management of familial dyslipoproteinemias.

Authors:  Peter O Kwiterovich
Journal:  Curr Cardiol Rep       Date:  2013-06       Impact factor: 2.931

Review 10.  Therapeutic RNA manipulation in liver disease.

Authors:  Thomas A Kerr; Nicholas O Davidson
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.